The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > About us > Scientific advisory board

Scientific advisory board

Pr Remy Burcelin, Ph.D

Chairman and Founder

Pr. Burcelin is a Research Director at the French national medical research institute (INSERM, Inserm/UPS  UMR 1048), where he has focused since 2007 on the molecular bases of insulin resistance and the role of the intestine (microflora & endocrine function) in the control of metabolic diseases. Pr. Burcelin is an internationally renowned specialist on glucoincretins (GLP-1 and GIP). He founded the European Club for the study of GLP-1 and is the actual president of this scientific association.

From 2000 to 2003 he was Assistant Professor at the Institute of Pharmacology and Toxicology headed by Pr. B. Thorens in Lausanne, Switzerland. Pr. Burcelin gained his PhD in molecular endocrinology in 1992 and completed his studies at Institut Jacques Monod (Paris, France) and the Albert Einstein College of Medicine (Pr.  M.J. Charron, New York, USA).

Pr. Burcelin is a member of the editorial board of Endocrinology, a reviewer for major journals in diabetes, and an advisor to many international pharmaceutical companies. He is also a member of several international societies, such as the French Society for Diabetes (SFD), the European Foundation for the Study of Diabetes (EFSD) and the American Diabetes Association (ADA). Pr Burcelin has authored more than 120 publications in international journals.